Purpose: Active surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance. Materials and Methods: We studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance. Results: At a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p¼0.01, 0.04, 0.04, The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
THE prostate specific antigen era has been associated with stage migration toward lower grade and stage prostate cancers such that the majority of newly diagnosed prostate neoplasms are apparently indolent. 1, 2 The number of prostate cancers identified each year far exceeds the number of lethal cases and there is over diagnosis of those cancers that may never progress or cause harm if left untreated. 3 In the U.S. most men diagnosed with low risk PCa undergo curative therapy, 2,4,5 thereby resulting in substantial overtreatment.
Active surveillance is a management strategy for PCa that can mitigate overtreatment by delaying intervention in patients whose tumors initially have features consistent with a low risk cancer and treating only when a more clinically significant malignancy is identified. Patients treated with AS undergo serial monitoring with serum PSA measurements, clinical examinations and repeat biopsies. Intervention is only recommended with evidence of a more aggressive tumor, usually based on changes in biopsy characteristics or PSA values.
In 2008 we established a multi-institutional AS cohort in response to the increasing evidence of PCa overtreatment and the need for a prospective platform for the discovery and validation of biomarkers of PCa outcomes. 6 We present the first analysis to our knowledge of clinical factors associated with outcomes in 905 participants enrolled in the Canary PASS, and provide detailed pathological data for a subset of the cohort who underwent radical prostatectomy after initial AS.
METHODS

Canary PASS Cohort
Canary PASS opened for enrollment in 2008. 6 The protocol (clinicaltrials.gov NCT00756665) was approved by institutional review boards at each of 9 clinical sites and a coordinating center. All men provided written informed consent for entry into this prospective, observational, AS study.
To sample the full spectrum of men using AS broad eligibility criteria were used, including histologically confirmed adenocarcinoma of the prostate, cT1-2 disease, no previous treatment for PCa and willingness to undergo serial monitoring while providing biospecimens for subsequent analysis. Participants must have undergone 10-core or greater biopsy within 1 year before enrollment, or 2 or more biopsies, 1 of which was in the 2 years before study enrollment. Although there was no restriction to the time between diagnosis and enrollment, the median time was 8.4 months (IQR 14.4), with 67% of the participants enrolled after the diagnostic biopsy and 22% enrolled after the first surveillance biopsy.
Participants were followed with serum PSA measurements every 3 months, clinical and digital rectal examination every 6 months, and repeat prostate biopsy 6 to 12, 24, 48 and 72 months after diagnosis. At least 10-core regimens were required and 91% of study biopsy regimens were 12-core or more.
Participants were considered to have adverse disease reclassification (referred to only as reclassification) on any increase in Gleason grade (primary or sum) on repeat biopsy and/or an increase in biopsy tumor volume, defined as an increase in the ratio of number of biopsy cores containing cancer-to-total number of cores, from less than 34% to 34% or more. Participants with disease reclassification were offered treatment. Those declining treatment were allowed to remain on study. Biopsies and radical prostatectomies were evaluated for Gleason score by genitourinary trained pathologists at each site using the 2005 WHO/International Society of Urological Pathology modified Gleason system. 7 De-identified demographic, clinical and pathological data were maintained in a central data repository. A collaboration agreement governing study conduct and data use was executed at participating institutions.
Statistical Analysis
We used PASS data collected through May 2013 when 909 participants were enrolled in the study. Four participants enrolled more than 10 years after initial diagnosis were excluded from analysis. Age, race, Gleason score and tumor volume (ratio of number of cores containing cancerto-total number of biopsy cores) were ascertained from the time of diagnosis. PSA was measured before PCa diagnosis. PSA density was calculated from the diagnostic PSA and the first available prostate volume. Clinical T-stage and BMI were from study enrollment.
Cases were stratified by NCCN risk criteria at diagnosis using the criteria of very low riskdcT1, PSA density less than 0.15, Gleason score 6 or less, 2 or fewer cores containing cancer, 50% or less of any core containing cancer; low riskdcT1/T2a, PSA less than 10 ng/ml, Gleason score 6 or less; intermediate riskdcT2b/T2c, PSA 10 to 20 ng/ml, Gleason score 7; and high riskdmeeting intermediate risk criteria except PSA greater than 20 ng/ml. 8 There were 462 participants with insufficient data to classify them as very low risk but who met the low risk criteria. Fisher's exact test was used to evaluate the relationship between risk classification and pathological outcome.
Continuous variables were categorized for meaningful clinical interpretation. Categorical variables were summarized using frequencies and percentages. Outcomes included time from diagnosis to grade reclassification, any pathological disease reclassification (grade and/or volume) or curative treatment. Participants without the event of interest were censored at the date of last study contact. A Kaplan-Meier curve was used to present the probability of disease reclassification or treatment over time. Median survival probabilities and confidence intervals were reported. Cox proportional hazards models were used to assess the association of clinical variables with reclassification or treatment. Univariate as well as multivariate models were applied to compare the unadjusted and adjusted hazards ratio for each variable. Statistical analysis was performed using SASÒ version 9.3 and R studio version 0.98.501.
RESULTS
Demographics of the cohort are displayed in table 1. Median age was 63 (IQR 9). Although PASS uses broad eligibility criteria, most participants (87%) met NCCN criteria for very low risk or low risk cancer at diagnosis. More than 99% of the cohort had stage cT2a or less disease, 93% had PSA less Overall 170 (19%) participants received treatment, including 115 (68%) who had associated disease reclassification and 55 (32%) who opted for treatment without study defined reclassification. Of these participants approximately 40% had increasing tumor volume yet did not meet the definition for volume reclassification, while the remainder had no identifiable reason for treatment. Of the 92 participants who were inactive 32 moved, 41 were lost to followup, 13 refused future contact and 6 died of causes other than PCa. There were no distant metastases or PCa deaths.
Kaplan-Meier estimates of time to disease reclassification or treatment are shown in figure 2 . The probability of a patient remaining on AS at 2, 5 and 10 years after diagnosis was 88%, 71% and 50%, respectively. Median time free of treatment, grade reclassification or any biopsy reclassification (grade and/or volume) was 10.0 years (95% CI 8.0, -), 8.6 years (95% CI 6.7, -) and 7.2 years (95% CI 6.2, -), respectively. Surgery was the most common form of treatment, with 105 men undergoing radical prostatectomy, 59 receiving radiation, 3 receiving hormones and 1 treated with cryotherapy. Data were available for 103 participants who underwent radical prostatectomy (table 4 and supplementary table 4 , http:// jurology.com/). Before surgery these men had undergone a mean of 2.5 biopsies (range 1 to 7). The biopsy most proximal to surgery had the highest Gleason score in all but 3 participants who had a negative biopsy and then underwent surgery. 
DISCUSSION
Overtreatment for low risk prostate cancer is one of the most important issues in PCa management and was a large factor in the U.S. Preventive Services Task Force recommendation against PSA screening. 9 Due to the relatively indolent natural history of low risk disease, active surveillance is an effective strategy to mitigate overtreatment by delaying or avoiding primary therapy. Multiple series have demonstrated no or very low PCa specific mortality. Nonetheless, current monitoring tools lack the specificity and sensitivity needed for many clinicians and patients to more broadly embrace AS for localized PCa, resulting in persistently high curative treatment rates in the U.S. 2 In our prospective, multicenter cohort with participants from 9 sites throughout North America, we demonstrated that in a diverse clinical setting AS delays or avoids active treatment with a median time free from treatment of more than 5 years, consistent with results from single center studies.
10e13 Interestingly a substantial proportion of patients who experience disease reclassification on AS do not opt for primary treatment, while many without reclassification opt for curative treatment during a relatively short followup.
The primary end point in our analysis was detection of higher grade or volume cancer on repeat prostate biopsy. This finding during AS may be due to actual disease evolution or, most often, to the presence of a higher grade or volume tumor that was missed due to undersampling of the prostate during biopsy. We use the term adverse reclassification (20) 58 (57) 1 (1) 17 (16) 2 (2) 3 (3) 1 (1) 35 (34) The biopsy with the highest Gleason score before surgery is shown (the biopsy immediately preceding surgery in all but 3 participants), along with Gleason score at the time of surgery. All but 2 participants were diagnosed with Gleason 3þ3 disease. Adverse pathology was defined as primary pattern 4 or 5, EPE, positive lymph nodes (N1) and/or SVI at the time of surgery.
rather than progression to describe our end point. Higher grade tumors are a more aggressive phenotype and generally have worse outcomes.
14e16
Similarly, a higher proportion of biopsy cores involved with cancer is correlated with disease stage and worse outcomes after primary treatment. 17, 18 While many series use 2 cores with cancer to define higher volume cancer, we chose a conservative threshold for reclassification of 34% of total biopsy cores containing cancer. 19 The use of PSA kinetics to define disease progression while on AS is controversial, 20 and although PSA kinetics are not currently used to define disease progression in PASS, PSA data are collected for evaluation as the cohort matures.
Our study shows that while clinical factors are related to disease reclassification, such associations are modest. We found significant but modest associations between adverse disease reclassification and PSA density, tumor volume and BMI. PSA density has been associated with time to treatment, progression and adverse pathological features in other AS cohorts, 10, 13, 21, 22 and is an eligibility criterion in some series. 12 In our experience prostate volume was inconsistently collected, suggesting that it is generally not used to influence AS decisions. Volume of cancer, defined by the proportion of total cores involved with cancer, is a surrogate measure for overall disease volume, which is correlated with worse disease specific outcomes. 23 Likewise, obesity has been associated with less favorable outcomes in a variety of cancers including PCa. 24 The PASS cohort included 103 participants who underwent radical prostatectomy after initial surveillance. Of these 103 patients 101 (98%) were initially diagnosed with Gleason 3þ3 disease. There were 61 (59%) men who experienced upgrading on biopsy before surgery, presumably leading to the decision to treat the cancer, while 41 men were treated with 3þ3 disease. Interestingly 24 of 41 (58%) participants who underwent prostatectomy for 3þ3 disease were found to have higher grade disease at surgery. Some of this upgrading is likely due to the previously described rates of intraobserver and interobserver variability. 25 Our pathological data demonstrate a poor correlation of initial risk group with adverse surgical pathology. Using a definition of adverse pathology of primary Gleason pattern 4-5 and/or nonorgan confined disease, participants who fulfilled the NCCN definition of very low risk, low risk or intermediate/high risk disease at diagnosis had adverse pathology at surgery at 37%, 32% and 40%, respectively, after a period of AS. In our cohort 2 participants had positive lymph nodes, both of whom underwent surgery less than 1 year after cancer diagnosis. One met NCCN criteria for very low risk disease at initial diagnosis (2 of 12 cores of 3þ3, less than 50% tumor per core), had pattern 3þ3 carcinoma in 3 of 12 cores with greater than 50% tumor in 1 core on repeat biopsy, and at surgery had pT3a, 3þ4 disease with 1 positive node. The other participant was diagnosed with low risk Gleason 3þ3 disease, had 4þ3 disease in 4 of 14 cores on repeat biopsy, and at surgery had pT2c, 4þ3 disease with a single positive node. While the interpretation of these observations is limited by small numbers, primarily of patients who experienced reclassification on followup, these data suggest that clinical characteristics alone are not sufficient to accurately distinguish indolent cancers from those that may be more aggressive. There is a clear need to move beyond PSA, stage and biopsy characteristics to a more biologically based assessment of risk at diagnosis as well as during periodic re-evaluation. The serial biospecimens collected in PASS will allow us to evaluate genomic and molecular diagnostic tests designed to distinguish aggressive cancers from those that will not cause harm if left untreated. 26 There are limitations of this study. Evaluation of the impact of AS on the more established disease specific end points, such as PCa metastasis or mortality, is not possible with our short followup. However, previous studies, including randomized clinical trials, 27 have shown that low risk disease is associated with low long-term disease mortality.
11
Similarly cancer reclassification in AS to higher grade or volume disease often represents undersampling at original prostate biopsy. However, the detection of intermediate risk disease in a man on AS would then permit therapeutic interventions that are more likely beneficial to the patient. 14, 19 Finally, central pathological review was not performed for the primary end point of biopsy reclassification. A benefit of this approach is that pathological evaluation in our multicenter study better reflects community practice.
CONCLUSIONS
At the time of diagnosis clinical characteristics alone do not completely distinguish indolent prostate cancers from those cancers that may benefit from early intervention, as evidenced by equal rates of adverse prostatectomy pathology among very low, low and intermediate risk disease at diagnosis. Better tools are needed to improve risk stratification. The PASS biorepository will allow for the validation of biomarkers to identify cases that may be better managed with treatment, vs those with a long-term prognosis allowing a less intensive followup schedule, and provide greater confidence in the appropriateness of a nontreatment management strategy.
